Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosfomycin/metronidazole - Reponex Pharmaceuticals

Next Previous
Drug Profile

Fosfomycin/metronidazole - Reponex Pharmaceuticals

Alternative Names: RNX-051

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reponex Pharmaceuticals
  • Class Anti-infectives; Antibacterials; Antiprotozoals; Epoxy compounds; Esters; Nitroimidazoles; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Phosphoric Acids; Radiosensitisers; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell wall inhibitors; DNA synthesis inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bacterial infections

Most Recent Events

  • 24 Aug 2026 Fosfomycin/metronidazole - Reponex Pharmaceuticals is available for licensing in Japan, United Arab Emirates as of 24 Aug 2026. 9473314
  • 14 Aug 2026 Reponex Pharmaceuticals plans enrolment of the first patient in clinical study in Germany in late 2026 or early 2027 (Parenteral)
  • 30 Jun 2026 Reponex Pharmaceuticals has patents pending related to fixed dose combination of Fosfomycin/metronidazole, prior to June 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top